A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer (P204)



Status:Recruiting
Conditions:Ovarian Cancer, Cervical Cancer, Cervical Cancer, Cancer, Cancer, Cancer, Endometrial Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/5/2018
Start Date:February 5, 2018
End Date:July 2020
Contact:Cynthia Sirard, MD
Email:csirard@leaptx.com
Phone:617-714-0357

Use our guide to learn which trials are right for you!

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in
Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial
Ovarian Cancer

This study employs a "basket" design to concurrently investigate DKN-01 as monotherapy and in
combination with paclitaxel in patients with recurrent epithelial endometrial cancer (EEC) or
recurrent epithelial ovarian cancer (EOC) (see Study Design for details). Thus, 4 distinct
patient groups are being independently investigated:

1. DKN-01 monotherapy in recurrent EEC (Group 1)

2. DKN-01+paclitaxel in recurrent EEC (Group 2)

3. DKN-01 monotherapy in recurrent EOC (Group 3)

4. DKN-01+paclitaxel in recurrent EOC (Group 4)

Inclusion Criteria:

1. Diagnosis:

1. Epithelial Endometrial Cancer: histologically confirmed diagnosis (by either
primary surgical specimen or biopsy for recurrence) of recurrent previously
treated EEC.

2. Epithelial Ovarian Cancer: histologically confirmed diagnosis (by either primary
surgical specimen or biopsy for recurrence) of recurrent
platinum-resistant/refractory EOC (i.e., disease recurrence within 6 months of
completion of or progression during platinum-based chemotherapy).

Note that patients with germ cell, sex cord stroma, carcinosarcoma, or sarcoma are
eligible only if the tumor has a mixed endometrioid component with a documented Wnt
signaling alteration.

2. Refractory or intolerant to at least one prior standard therapy(ies) for metastatic or
locally advanced disease.

1. If prior therapy consisted of palliative chemoradiation therapy, it will be
considered one line of therapy.

2. Prior treatment with paclitaxel as part of definitive therapy regimen is
acceptable, provided the patient is not intolerant of paclitaxel.

3. Patients who are not eligible to receive paclitaxel will be allowed to receive
single agent DKN-01.

3. Tumor tissue for mandatory pre-treatment and on-treatment biopsies.

4. One or more tumors measurable on radiographic imaging as defined by RECIST 1.1.

5. Ambulatory and ≥18 years of age.

6. ECOG performance status (PS) of 0 or 1

a. ECOG PS of 2 may be eligible upon the review and approval of the Medical Monitor.

7. Estimated life expectancy of at least 3 months, in the judgment of the Investigator.

8. Disease-free of active second/secondary or prior malignancies for ≥2 years with the
exception of currently treated basal cell, squamous cell carcinoma of the skin, or
carcinoma in-situ of the cervix or breast.

9. Acceptable liver, renal, hematologic and coagulation function

10. Females of child bearing potential and male partners of female patients must agree to
use adequate contraception during the study and for 6 months after their last dose of
study drug.

11. Reliable and willing to make themselves available for the duration of the study and
are willing to follow study-specific procedures.

12. Provided written informed consent prior to any study-specific procedures.

Exclusion Criteria:

1. Patients with the following pure histologies of endometrial or ovarian cancer are not
eligible for enrollment: germ cell, sex cord stroma, carcinosarcoma, or sarcoma.

2. New York Heart Association Class III or IV cardiac disease, myocardial infarction
within the past 6 months, or unstable arrhythmia.

3. Fridericia-corrected QT interval (QTcF) > 470 msec (female) or history of congenital
long QT syndrome.

4. Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study
entry requiring systemic therapy.

5. Known to be human immunodeficiency virus (HIV) positive, have hepatitis B surface
antigen (HBSAg), or hepatitis C antibodies (HCAb), unless hepatitis C virus
ribonucleic acid (HCV RNA) undetected/negative.

6. History of major organ transplant (i.e., heart, lungs, liver, or kidney).

7. History of autologous/allogenic bone marrow transplant.

8. Serious nonmalignant disease

9. Pregnant or nursing.

10. History of osteonecrosis of the hip or have evidence of structural bone abnormalities
in the proximal femur on MRI scan that are symptomatic and clinically significant.

11. Symptomatic central nervous system (CNS) malignancy or metastasis.

12. Known osteoblastic bony metastasis

13. Treatment with surgery or chemotherapy within 21 days prior to study entry (42 days
for nitrosoureas or mitomycin C)

14. Any hormonal therapy directed at the malignant tumor must be discontinued at least one
week prior to study entry.

15. Clinically significant peripheral neuropathy at the time of study entry. Patients with
pre-existing peripheral neuropathy will be allowed to receive single agent DKN-01

16. History of hypersensitivity reactions to paclitaxel or other drugs formulated in
Cremophor® EL (polyoxyethylated castor oil). Patients who exhibit these
hypersensitivities will be eligible to receive single agent DKN-01

17. Prior radiation therapy within 14 days prior to study entry

18. Currently receiving any other investigational agent or received an investigational
agent within last 30 days of study entry.

19. Previously treated with an anti-DKK1 therapy

20. Significant allergy to a pharmaceutical therapy that, in the opinion of the
Investigator, poses an increased risk to the patient

21. Active substance abuse
We found this trial at
15
sites
Madison, Wisconsin 53792
(608) 263-2400
Principal Investigator: Lisa Barroilhet, MD
Phone: 608-263-0796
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
?
mi
from
Madison, WI
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Cesar Castro, MD
Phone: 617-643-5150
?
mi
from
Boston, MA
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Linda Duska, MD
Phone: 434-982-6657
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Haider Mahdi, MD
Phone: 216-445-8090
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Birmingham, Alabama 35294
Principal Investigator: Rebecca Arend, MD
Phone: 205-934-6454
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Phone: 617-632-2668
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
Principal Investigator: David Miller, MD
Phone: 214-648-1479
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Germantown, Tennessee 38138
Principal Investigator: Adam ElNaggar, MD
Phone: 901-683-0055
?
mi
from
Germantown, TN
Click here to add this to my saved trials
Hilliard, Ohio 43026
Principal Investigator: David O'Malley, MD
Phone: 614-685-6411
?
mi
from
Hilliard, OH
Click here to add this to my saved trials
Kansas City, Missouri 64132
Principal Investigator: Kristopher LyBarger, MD
Phone: 816-276-9698
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
9200 W Wisconsin Ave
Milwaukee, Wisconsin 53226
(414) 805-3666
Principal Investigator: William Bradley, MD
Phone: 414-805-5337
Froedtert and the Medical College of Wisconsin Froedtert Health combines with the Medical College of...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
615-320-5090
Principal Investigator: Erika P Hamilton, MD
Phone: 615-329-7613
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
Principal Investigator: Camille Gunderson, MD
Phone: 405-271-8777
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Scottsdale, Arizona 85258
Principal Investigator: Jasgit Sachdev, MD
Phone: 623-238-7667
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
1309 North Flagler Drive
West Palm Beach, Florida 33401
Principal Investigator: Howard Goodman, MD
Phone: 561-472-1696
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials